Investigational drug · Phase 3
CLR 131
Also called: I-131-CLR1404, Iopofosine I 131 single dose, Iopofosine I 131 multiple dose, Iopofosine I 131 fractionated dose, Iopofosine I 131
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Waldenstrom Macroglobulinemia, Multiple Myeloma, Chronic Lymphocytic Leukemia.
Phase 3Last checked: Nov 19, 2026Latest source record: Aug 14, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
2
2 still active
All registered trials
11
Any phase or sponsor naming "CLR 131"
First trial start
2017
Jul 26, 2017
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "CLR 131", any sponsor or status.
Conditions studied
As listed on its trial records.
- Waldenstrom Macroglobulinemia
- Multiple Myeloma
- Chronic Lymphocytic Leukemia
- Small Lymphocytic Lymphoma
- Lymphoplasmacytic Lymphoma
- Marginal Zone Lymphoma
- Mantle Cell Lymphoma
- Diffuse Large B Cell Lymphoma
- Central Nervous System Lymphoma
- Waldenstrom Macroglobulinaemia
Approved drugs for the same conditions: Multiple myeloma · Chronic lymphocytic leukemia · Lymphoma (non-Hodgkin) · Hematology and blood cancers
Largest trials
Live from ClinicalTrials.gov: studies naming "CLR 131" as an intervention, largest first.
- Evaluation of Iopofosine I 131 vs. R-CD in WM PatientsPivotal-lookingNot yet recruiting
Cellectar Biosciences, Inc.Industry
NCT07766421 · 219 participants (planned) · Start Dec 2026 · Primary completion Jan 2032
Drug: Iopofosine I 131; Rituximab (active comparator) and 2 more · For: Waldenstrom Macroglobulinaemia; Waldenstrom Macroglobulinemia; Waldenstrom's Macroglobulinaemia Refractory and 2 more
- Study of Iopofosine I-131 (CLR 131) in Select B-Cell Malignancies (CLOVER-1) With Expansion in WaldenstromActive, not recruiting
Cellectar Biosciences, Inc.Industry
NCT02952508 · 120 participants (planned) · Start Jul 26, 2017 · Primary completion Jun 22, 2026
Drug: Iopofosine I 131 single dose; Iopofosine I 131 multiple dose and 1 more · For: Waldenstrom Macroglobulinemia; Multiple Myeloma; Chronic Lymphocytic Leukemia and 6 more
Sites: Los Angeles, California; Redlands, California; Washington D.C., District of Columbia · 52 sites in all
Cellectar Biosciences, Inc.Industry
NCT07311993 · 60 participants (planned) · Start Dec 5, 2025 · Primary completion Feb 2028
Drug: Iopofosine I 131; CLR 125 · For: Breast Cancer
Sites: Jacksonville, Florida; Glen Burnie, Maryland; Rochester, Minnesota · 4 sites in all
- Novel Targeted Radiotherapy in Pediatric Patients With Inoperable Relapsed or Refractory HGGActive, not recruiting
Cellectar Biosciences, Inc.Industry
NCT05610891 · 50 participants (planned) · Start Oct 1, 2023 · Primary completion Jun 30, 2027
Drug: CLR 131 · For: High-Grade Glioma
Sites: Palo Alto, California; New York, New York; Cincinnati, Ohio · 8 sites in all
- Dose Escalation Study of I-131-CLR1404 in Patients With Relapsed or Refractory Multiple MyelomaCompleted
Cellectar Biosciences, Inc.Industry
NCT02278315 · 31 participants · Start Feb 2015 · Primary completion Dec 9, 2020
Drug: I-131-CLR1404; dexamethasone and 1 more · For: Multiple Myeloma
Sites: Jacksonville, Florida; Maywood, Illinois; Detroit, Michigan · 4 sites in all
- Dose Escalation Study of CLR 131 in Pediatric Relapsed/Refractory Malignant Tumors Including Neuroblastoma and SarcomasActive, not recruiting
Cellectar Biosciences, Inc.Industry
NCT03478462 · 30 participants (planned) · Start Apr 30, 2019 · Primary completion Jun 30, 2027
Drug: CLR 131 · For: Pediatric Solid Tumor; Pediatric Lymphoma; Pediatric Brain Tumor and 5 more
Sites: Palo Alto, California; New York, New York; Chapel Hill, North Carolina · 8 sites in all
University of Wisconsin, MadisonAcademic, hospital or other
NCT04105543 · 12 participants · Start Dec 20, 2019 · Primary completion Sep 19, 2022
Drug: CLR 131 · For: Head and Neck Cancer
Sites: Johnson Creek, Wisconsin; Madison, Wisconsin
Cellectar Biosciences, Inc.Industry
NCT01495663 · 12 participants · Start Dec 2011 · Primary completion Nov 2013
Drug: I-131-CLR1404 · For: Cancer
Sites: Duarte, California; Washington D.C., District of Columbia; Madison, Wisconsin
- Dosimetry Study of I-131-CLR1404 in Patients With Relapsed or Refractory Advanced Solid TumorsCompleted
Cellectar, IncIndustry
NCT00925275 · 9 participants (planned) · Start Jun 2009 · Primary completion Feb 2010
Drug: I-131-CLR1404 · For: Solid Tumors
Sites: Duarte, California; Washington D.C., District of Columbia; Baltimore, Maryland · 4 sites in all
- Imaging Trial With I-124-CLR1404 in Patients With Newly Diagnosed or Recurrent GlioblastomaTerminated
Cellectar Biosciences, Inc.Industry
NCT01898273 · 7 participants · Start Feb 2014 · Primary completion Sep 2015
Drug: I-124-CLR1404 · For: Glioblastoma
Sites: Duarte, California; Tampa, Florida; Baltimore, Maryland · 9 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- Longitudinal Swallowing and Salivary Changes With CLR 131 and Re-Irradiation in Recurrent Head and Neck Cancer.
Wu J, Gustafson S, Hyun M, et al. · Head Neck 2026
- Safety and toxicity of Iopofosine I 131 (CLR 131) with external beam radiation therapy in recurrent or metastatic head and neck cancer: results of a phase 1 single-centre, open-label, single-arm, dose escalation and dose expansion study.
Bruce JY, Burr A, Kimple RJ, et al. · EBioMedicine 2025
- Voxel-Level Dosimetry for Combined Iodine 131 Radiopharmaceutical Therapy and External Beam Radiation Therapy Treatment Paradigms for Head and Neck Cancer.
Adam DP, Grudzinski JJ, Marsh IR, et al. · Int J Radiat Oncol Biol Phys 2024
- A study of the mechanical properties of as-received and intraorally exposed single-crystal and polycrystalline orthodontic ceramic brackets.
Alexopoulou E, Polychronis G, Konstantonis D, et al. · Eur J Orthod 2020
- Radiopharmaceuticals for Treatment of Osteosarcoma.
Anderson PM · Adv Exp Med Biol 2020
- Preclinical Pharmacokinetics and Dosimetry Studies of 124I/131I-CLR1404 for Treatment of Pediatric Solid Tumors in Murine Xenograft Models.
Marsh IR, Grudzinski J, Baiu DC, et al. · J Nucl Med 2019
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.